We are live on ! Find out more
CTOR

Citius Oncology
CTOR

6 hedge funds and large institutions have $97.7K invested in Citius Oncology in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

0.13% less ownership

Funds ownership: 0.28% → 0.15% (-0.13%)

45% less funds holding

Funds holding: 11 → 6 (-5)

58% less capital invested

Capital invested by funds: $230K → $97.7K (-$133K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 5

Holders
6
Holders Change
-5
Holders Change %
-45.45%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
1
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$26.7K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$8.45K

Top Sellers

Rank Fund Capital Flow
1
HF
HRT Financial
New York
-$78K
2
Citadel Advisors
Citadel Advisors
Florida
-$26.1K
3
XT
XTX Topco
Cayman Islands
-$24.3K
4
Renaissance Technologies
Renaissance Technologies
New York
-$12.9K
5
Osaic Holdings
Osaic Holdings
Arizona
-$5.5K

CTOR Hedge Fund Activity: Q1 2025 in Review

6 of the 7,476 institutional investors tracked by Wall St. Rank reported a position in Citius Oncology (CTOR) for Q1 2025, worth a combined $97.7K — down 58% from $230K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of CTOR and 0 opened new positions — a net loss of 5 holders — while 1 trimmed existing stakes and 2 added.

The largest buyer was UBS Group, adding an estimated $26.7K. The largest seller was HRT Financial, exiting entirely with an estimated $78K sold.

  • 6 institutional investors held Citius Oncology (CTOR) as of Q1 2025, down from 11 in Q4 2024.
  • Funds reported $97.7K of Citius Oncology stock for Q1 2025, down 58% quarter-over-quarter.
  • 0 funds opened new Citius Oncology positions in Q1 2025 and 5 closed out, a net change of -5 holders.
  • The largest Citius Oncology buyer in Q1 2025 was UBS Group, an estimated $26.7K added.
  • The largest Citius Oncology seller in Q1 2025 was HRT Financial, an estimated $78K sold.

Based on aggregated 13F filings for Q1 2025.